Entering text into the input field will update the search result below

QNCX Quince Therapeutics, Inc.
Stock Price & Overview

$0.960.07 (+7.87%)3:59 PM 12/01/23
NASDAQ | $USD | Post-Market: $0.96 4:00 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

People Also Follow

Company Profile

Quince Therapeutics, Inc. logo
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
  • 601 Gateway Blvd
  • Ste 1250
  • South San Francisco, CA, 94080
  • United States
Phone Number
415 910 5717
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.